Abstract
The current vaccine against TB, bacille Calmette-Guèrin (BCG) fails to protect against the most prevalent disease form, the pulmonary TB in adults. Thus, it is not a satisfactory vaccine.
Given that T cells are central to protection against TB, future vaccine design should focus on T-lymphocyte populations. Most vaccines do not prevent infection but instead disease, that if they allow establishment of the pathogen in the host but prevent its harmful effects.
The development of synthetic peptide-based immunogens is emerging as a possible approach in human vaccination in the future, as a replacement for conventional vaccines that use killed or attenuated whole microorganisms. The advantages of such synthetic vaccines (high potency, low adverse reactions, low cross-reactivity and high stability) are offset somewhat by the poorer inherent immunogenicity of these constructs. There is a greater need therefore to develop adjuvant/carrier systems to increase the immunogenicity of these newer vaccine candidates.
Keywords: Adjuvants, peptidic vaccine, proteomics, subunit approach, BCG, TB, tuberculosis.
Current Drug Targets
Title:Strategies for Developing Tuberculosis Vaccines: Emerging Approaches
Volume: 14 Issue: 9
Author(s): Adriano Mollica, Azzurra Stefanucci and Roberto Costante
Affiliation:
Keywords: Adjuvants, peptidic vaccine, proteomics, subunit approach, BCG, TB, tuberculosis.
Abstract: The current vaccine against TB, bacille Calmette-Guèrin (BCG) fails to protect against the most prevalent disease form, the pulmonary TB in adults. Thus, it is not a satisfactory vaccine.
Given that T cells are central to protection against TB, future vaccine design should focus on T-lymphocyte populations. Most vaccines do not prevent infection but instead disease, that if they allow establishment of the pathogen in the host but prevent its harmful effects.
The development of synthetic peptide-based immunogens is emerging as a possible approach in human vaccination in the future, as a replacement for conventional vaccines that use killed or attenuated whole microorganisms. The advantages of such synthetic vaccines (high potency, low adverse reactions, low cross-reactivity and high stability) are offset somewhat by the poorer inherent immunogenicity of these constructs. There is a greater need therefore to develop adjuvant/carrier systems to increase the immunogenicity of these newer vaccine candidates.
Export Options
About this article
Cite this article as:
Mollica Adriano, Stefanucci Azzurra and Costante Roberto, Strategies for Developing Tuberculosis Vaccines: Emerging Approaches, Current Drug Targets 2013; 14 (9) . https://dx.doi.org/10.2174/1389450111314090002
DOI https://dx.doi.org/10.2174/1389450111314090002 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Nanosuspensions of Poorly Water Soluble Drugs Prepared by Top-down Technologies
Current Pharmaceutical Design Antimicrobial Peptides with pH-Dependent Activity and Alkaline Optima: Their Origins, Mechanisms of Action and Potential Applications
Current Protein & Peptide Science Mitochondria-Mediated Oxidative Stress: Old Target for New Drugs
Current Medicinal Chemistry Glycine Rich P-loop Motif in Deoxyuridine Pyrophosphatase
Current Protein & Peptide Science iMTBGO: An Algorithm for Integrating Metabolic Networks with Transcriptomes Based on Gene Ontology Analysis
Current Genomics Increment of Antimycobaterial Activity on Lichexanthone Derivatives
Medicinal Chemistry Promising Drugs Against Tuberculosis
Recent Patents on Anti-Infective Drug Discovery Potential MicroRNA Targets for Cancer Chemotherapy
Current Medicinal Chemistry Prevention and Therapeutic Strategies of Thromboembolic Events in Patients with Inflammatory Bowel Diseases: A Report of Three Cases
Current Drug Targets Specific Targeting of Engineered Nanoparticles to Activated Macrophages
Current Nanoscience Herbal Folklore Medication for Liver Disorders
Current Traditional Medicine The Role of Infection in Carotid Plaque Pathogenesis and Stability: The Clinical Evidence
Current Vascular Pharmacology Ribonucleotide Reductase: A Critical Enzyme for Cancer Chemotherapy and Antiviral Agents
Recent Patents on Anti-Cancer Drug Discovery Evaluation of Molecular Docking Using Polynomial Empirical Scoring Functions
Current Drug Targets Lactoferrin as a Natural Immune Modulator
Current Pharmaceutical Design The Fungal Metabolites with Potential Antiplasmodial Activity
Current Medicinal Chemistry A Developmental Approach to Drug-induced Liver Injury in Newborns and Children
Current Medicinal Chemistry Drug Susceptibility of the Mycobacterium Genus: In Vitro Tests and Clinical Implications
Current Clinical Pharmacology Imidazole Scaffold Based Compounds in the Development of Therapeutic Drugs
Current Topics in Medicinal Chemistry Chemical Constituents and Biological Activities of Simira Genus: A Contribution to the Chemotaxonomic of Rubiaceae Family
The Natural Products Journal